Shanghai Shyndec Pharmaceutical Yönetim

Yönetim kriter kontrolleri 2/4

We currently do not have sufficient information about the CEO.

Anahtar bilgiler

Yong Liu

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2.3yrs
Yönetim Kurulu ortalama görev süresi	3.6yrs

Son yönetim güncellemeleri

Recent updates

CEO

Yong Liu (55 yo)

less than a year

Görev süresi

Mr. Yong Liu is Vice Chairman of the Board of Shanghai Shyndec Pharmaceutical Co., Ltd. from April 28, 2021 and serves as President Since September 2024.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yong Liu	Vice Chairman of the Board & President	less than a year	Veri yok	Veri yok
Xian Lin Li	VP & General Counsel	2.6yrs	CN¥1.43m	0.0015% CN¥ 240.4k
Dongsong Wei	VP & Secretary of the Board of Directors	13.3yrs	CN¥1.46m	0.0015% CN¥ 240.4k
Zhong Gong	Vice President	20.4yrs	CN¥1.43m	0.0015% CN¥ 240.4k
Feng Ni	Vice President	2yrs	CN¥914.60k	0.0015% CN¥ 240.4k
Jing Zu	Chief Financial Officer	less than a year	CN¥344.90k	Veri yok

2.3yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim: 600420's management team is considered experienced (2.3 years average tenure).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yong Liu	Vice Chairman of the Board & President	3.6yrs	Veri yok	Veri yok
Yingqi Li	Independent Director	2yrs	CN¥240.00k	Veri yok
Peng Wang	Director	2yrs	Veri yok	Veri yok
Ru Li	Director	2yrs	Veri yok	Veri yok
Zenghe Dong	Chairman	5.8yrs	Veri yok	Veri yok
Xiangdong Yu	Supervisor	5.8yrs	Veri yok	0.0015% CN¥ 240.4k
Kan Tian	Independent Director	5.8yrs	CN¥240.00k	Veri yok
Yonggang Xing	Chairman of the Supervisory Board	5yrs	Veri yok	Veri yok
Shuyuan Wei	Director	4.5yrs	Veri yok	Veri yok
Fanhong Wu	Independent Director	3.6yrs	CN¥240.00k	Veri yok
Yonghua Zuo	Supervisor	2yrs	Veri yok	Veri yok

3.6yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 600420's board of directors are considered experienced (3.6 years average tenure).

Shanghai Shyndec Pharmaceutical Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Shanghai Shyndec Pharmaceutical Co., Ltd., Annual General Meeting, May 28, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.16 in 3Q 2023)

Investor sentiment deteriorates as stock falls 15%

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.13 in 2Q 2023)

Investor sentiment improves as stock rises 17%

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Shanghai Shyndec Pharmaceutical Co., Ltd., Annual General Meeting, May 28, 2024

First quarter 2024 earnings released: EPS: CN¥0.25 (vs CN¥0.15 in 1Q 2023)

Investor sentiment improves as stock rises 15%

Full year 2023 earnings released: EPS: CN¥0.54 (vs CN¥0.61 in FY 2022)

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in FY 2022)

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.14 in 2Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.14 in 2Q 2022)

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023

First quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.076 in 1Q 2022)

Investor sentiment improves as stock rises 20%

Full year 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.55 in FY 2021)

Shanghai Shyndec Pharmaceutical Co., Ltd. announced that it has received CNY 1.199999999 billion in funding from China National Pharmaceutical Group Corporation

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.20 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.20 in 2Q 2021)

Shanghai Shyndec Pharmaceutical Co., Ltd.(XSSC:600420) dropped from S&P Global BMI Index

Shanghai Shyndec Pharmaceutical Co., Ltd.(XSSC:600420) dropped from S&P Global BMI Index

First quarter 2022 earnings released: EPS: CN¥0.076 (vs CN¥0.21 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.55 (vs CN¥0.63 in FY 2020)

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.30 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.19 in 2Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.19 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.13 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.63 (vs CN¥0.62 in FY 2019)

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day low: CN¥8.47

New 90-day low: CN¥9.01

New 90-day low: CN¥9.42

New 90-day high: CN¥10.68

Third quarter earnings released

New 90-day low: CN¥9.49

First half earnings released

New 90-day high - CN¥10.64

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş